MX2013003498A - Derivados de cromeno. - Google Patents

Derivados de cromeno.

Info

Publication number
MX2013003498A
MX2013003498A MX2013003498A MX2013003498A MX2013003498A MX 2013003498 A MX2013003498 A MX 2013003498A MX 2013003498 A MX2013003498 A MX 2013003498A MX 2013003498 A MX2013003498 A MX 2013003498A MX 2013003498 A MX2013003498 A MX 2013003498A
Authority
MX
Mexico
Prior art keywords
chromene derivatives
chromene
derivatives
nkc
tcr
Prior art date
Application number
MX2013003498A
Other languages
English (en)
Other versions
MX342960B (es
Inventor
Peypoch Angel Messeguer
Sanchez Balbino Jose Alarcon
De Leon Antonio Morreale
Revuelta Aldo Jorge Borroto
Rojo Irene Azahara Arellano
Requena Almudena Perona
Romero Esther Carrasco
Original Assignee
Consejo Superior Investigacion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior Investigacion filed Critical Consejo Superior Investigacion
Publication of MX2013003498A publication Critical patent/MX2013003498A/es
Publication of MX342960B publication Critical patent/MX342960B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

Derivados de cromeno de fórmula I, donde los significados para los distintos sustituyentes son los indicados en la descripción; estos compuestos son útiles como inhibidores de la interacción TCR-Nkc en linfocitos T. (Ver Formula).
MX2013003498A 2010-09-28 2011-07-08 Derivados de cromeno. MX342960B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201031437A ES2379242B1 (es) 2010-09-28 2010-09-28 Derivados de cromeno.
PCT/ES2011/070506 WO2012042078A1 (es) 2010-09-28 2011-07-08 Derivados de cromeno

Publications (2)

Publication Number Publication Date
MX2013003498A true MX2013003498A (es) 2013-05-20
MX342960B MX342960B (es) 2016-10-18

Family

ID=45892008

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003498A MX342960B (es) 2010-09-28 2011-07-08 Derivados de cromeno.

Country Status (17)

Country Link
US (1) US9120764B2 (es)
EP (1) EP2623503B1 (es)
JP (1) JP5894164B2 (es)
KR (1) KR101800919B1 (es)
CN (1) CN103189367B (es)
AU (1) AU2011310078B2 (es)
BR (1) BR112013007073B1 (es)
CA (1) CA2813144C (es)
DK (1) DK2623503T3 (es)
ES (1) ES2379242B1 (es)
HK (1) HK1186727A1 (es)
HR (1) HRP20151378T1 (es)
HU (1) HUE025731T2 (es)
MX (1) MX342960B (es)
PL (1) PL2623503T3 (es)
PT (1) PT2623503E (es)
WO (1) WO2012042078A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201602982YA (en) * 2013-10-17 2016-05-30 Abbvie Deutschland Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
ES2534336B1 (es) * 2013-10-18 2016-01-28 Artax Biopharma Inc. Derivados de cromeno como inhibidores de la interacción TCR-Nck
ES2534318B1 (es) * 2013-10-18 2016-01-28 Artax Biopharma Inc. Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck
US9968604B2 (en) 2015-04-16 2018-05-15 Chiesi Farmaceutici S.P.A. Chromene derivatives as phoshoinositide 3-kinases inhibitors
WO2019169001A1 (en) 2018-02-27 2019-09-06 Artax Biopharma Inc. Chromene derivatives as inhibitors of tcr-nck interaction

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001278980A1 (en) * 2000-07-21 2002-02-05 Chugai Seiyaku Kabushiki Kaisha Coumarin derivatives useful as tnfalpha inhibitors
TW200529845A (en) * 2003-12-12 2005-09-16 Wyeth Corp Quinolines useful in treating cardiovascular disease
CA2656706C (en) * 2006-07-06 2016-09-20 Cytovia, Inc. Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof
ES2331451B1 (es) * 2008-06-30 2010-10-21 Consejo Superior De Investigaciones Cientificas (Csic) Inmunosupresor basado en la interrupcion de la interaccion tcr-nck.
BRPI0922135B1 (pt) * 2008-12-05 2021-07-13 Astellas Pharma Inc Composto de 2h-cromeno ou um sal do mesmo, composição farmacêutica compreendendo dito composto e uso do mesmo para prevenir ou tratar uma doença induzida por infiltração de linfócito indesejável associada com s1p1

Also Published As

Publication number Publication date
RU2013117924A (ru) 2014-11-10
HUE025731T2 (en) 2016-05-30
EP2623503A4 (en) 2014-03-05
CA2813144C (en) 2018-10-30
JP5894164B2 (ja) 2016-03-23
CN103189367B (zh) 2016-06-08
ES2379242B1 (es) 2013-03-04
KR101800919B1 (ko) 2017-11-23
AU2011310078A1 (en) 2013-04-11
HRP20151378T1 (hr) 2016-01-15
MX342960B (es) 2016-10-18
BR112013007073A2 (pt) 2020-04-28
US20140005247A1 (en) 2014-01-02
KR20130141481A (ko) 2013-12-26
JP2013537899A (ja) 2013-10-07
ES2379242A1 (es) 2012-04-24
PT2623503E (pt) 2016-01-26
PL2623503T3 (pl) 2016-04-29
AU2011310078B2 (en) 2016-12-15
BR112013007073B1 (pt) 2021-11-16
EP2623503A1 (en) 2013-08-07
WO2012042078A1 (es) 2012-04-05
HK1186727A1 (zh) 2014-07-04
CN103189367A (zh) 2013-07-03
US9120764B2 (en) 2015-09-01
CA2813144A1 (en) 2012-04-05
DK2623503T3 (en) 2016-01-11
EP2623503B1 (en) 2015-09-23

Similar Documents

Publication Publication Date Title
PH12016501375A1 (en) Pyridin-2-amides useful as cb2 agonists
PH12015501083A1 (en) Novel pyridine derivatives
PH12015501843A1 (en) Novel pyrazol derivatives
PH12015501073A1 (en) Novel pyridine derivatives
MX2011011094A (es) Derivados de prolina como inhibidores de catepsina.
PH12014502169A1 (en) N-cyclylamides as nematicides
NZ597517A (en) 5-fluoropyrimidinone derivatives
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
PH12015501933B1 (en) Novel pyridine derivatives
MX346248B (es) Derivados de [1,2,3]triazol[4,5-d]pirimidina como agonistas de los agonistas del receptor canabinoide 2.
MX2014004920A (es) Nuevos derivados de pirazina.
PH12015502471A1 (en) Purine derivatives as cb2 receptor agonists
NZ597570A (en) N1-acyl-5-fluoropyrimidinone derivatives
NZ597483A (en) N1-substituted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
MX342960B (es) Derivados de cromeno.
MX346090B (es) Derivados de pirrolidina usados como inhibidores de catepsina.
MX363458B (es) Nuevos derivados de tetrazolona.
MX2014008918A (es) Nuevos derivados de pirrolidina.
AU2013347232A8 (en) 3-Aminocyclopentane carboxamide derivatives
PH12015500262A1 (en) Novel pyridine derivatives
MX351093B (es) Nuevos derivados de azetidina.

Legal Events

Date Code Title Description
FG Grant or registration